ImmunoGen: Possible Accelerated FDA Approval For Ovarian Cancer Treatment

Jun. 20, 2022 2:51 PM ETImmunoGen, Inc. (IMGN) StockLLY, IMGN6 Comments
Terry Chrisomalis
Investing Group Leader

Summary

  • PDUFA date with Priority Review for mirvetuximab for treatment of ovarian cancer patients with high folate receptor alpha set for November 28, 2022.
  • Confirmatory MIRASOL study trial readout of mirvetuximab for treatment of ovarian cancer patients with high folate receptor alpha expected early 2023.
  • Results from phase 2 CADENZA study using pivekimab sunirine for treatment of frontline and relapsed/refractory blastic plasmacytoid dendritic cell neoplasm patients expected before end of 2022.
  • Results from phase 1b/2 triple combination study using pivekimab sunirine + Azacitidine + Venetoclax for the treatment of patients with acute myeloid leukemia expected before end of 2022.
  • This idea was discussed in more depth with members of my private investing community, Biotech Analysis Central. Learn More »

Female scientist examining toxic liquid in laboratory.

skynesher/E+ via Getty Images

ImmunoGen (IMGN) is a speculative biotech that you should keep your eye on. That's because it trades only at around $3.71 per share and is rapidly approaching towards the end of 2022 with possible Accelerated

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33.50% discount price of $399 per year.

This article was written by

Terry Chrisomalis
13.46K Followers

Terry Chrisomalis is a private investor in the Biotech sector with years of experience utilizing his Applied Science background to generate long term value from Healthcare.

He is the author of the investing group Biotech Analysis Central which contains a library of 600+ Biotech investing articles, a model portfolio of 10+ small and mid-cap stocks with deep analysis for each, live chat, and a range of analysis and news reports to help Healthcare investors make informed decisions.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

More on IMGN

Trending Analysis

Trending News